DRD2 and psychiatric disorder: Chlorpromazine (CPZ), an FDA- and EMA-approved antipsychotic medication, has been a mainstay of clinical practice in psychiatric disorders for over seven decades, due to its well-characterized ability to antagonize dopamine at the level of the CNS dopamine receptor D2 (DRD2).